Intellia Therapeutics Stock Investor Sentiment
| NTLA Stock | USD 15.59 0.52 3.23% |
About 68% of Intellia Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Intellia Therapeutics suggests that many traders are alarmed. The current market sentiment, together with Intellia Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Intellia Therapeutics stock news signals to limit their universe of possible portfolio assets.
Comfort Level 32
Alarmed
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Intellia Therapeutics' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Intellia Therapeutics.
News SentimentBullish | Hype SentimentBearish | Insider SentimentDisposing |
Intellia Historical Sentiment
Although Intellia Therapeutics' investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding Intellia, such as negative comments on social media and news outlets, may cause fear in the market and push Intellia Therapeutics' investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of Intellia.
Intellia Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Intellia Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Intellia Therapeutics Historical Investor Sentiment
Investor biases related to Intellia Therapeutics' public news can be used to forecast risks associated with an investment in Intellia. The trend in average sentiment can be used to explain how an investor holding Intellia can time the market purely based on public headlines and social activities around Intellia Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Intellia Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Intellia Therapeutics and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Intellia Therapeutics news discussions. The higher the estimate score, the more favorable the investor's outlook on Intellia Therapeutics.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of Intellia Therapeutics' Stock prices. Below is the latest headlines and news related to Intellia Therapeutics Stock. Current markets are slightly bearish. About 53% of major world exchanges and indexes are down. See today's market update for more information.
There is far too much social signal, news, headlines, and media speculation about Intellia Therapeutics that are available to investors today. This information is accessible both publicly - through Intellia Therapeutics' media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of Intellia-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of Intellia Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Intellia Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Intellia Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Intellia Therapeutics alpha.
Intellia Largest EPS Surprises
Earnings surprises can significantly impact Intellia Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2017-10-31 | 2017-09-30 | -0.5 | -0.44 | 0.06 | 12 | ||
2018-05-01 | 2018-03-31 | -0.58 | -0.51 | 0.07 | 12 | ||
2020-08-06 | 2020-06-30 | -0.69 | -0.61 | 0.08 | 11 | ||
2021-02-25 | 2020-12-31 | -0.6 | -0.69 | -0.09 | 15 | ||
2017-03-14 | 2016-12-31 | -0.22 | -0.31 | -0.09 | 40 | ||
2019-05-02 | 2019-03-31 | -0.59 | -0.49 | 0.1 | 16 |
There is far too much social signal, news, headlines, and media speculation about Intellia Therapeutics that are available to investors today. This information is accessible both publicly - through Intellia Therapeutics' media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of Intellia-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of Intellia Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Intellia Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Intellia Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Intellia Therapeutics alpha.
Intellia Therapeutics Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Disposition of 1547 shares by Goodman Jesse of Intellia Therapeutics at 9.56 subject to Rule 16b-3 | 06/30/2025 |
2 | Disposition of 1547 shares by Goodman Jesse of Intellia Therapeutics at 9.23 subject to Rule 16b-3 | 07/01/2025 |
3 | Disposition of 2503 shares by Michael Dube of Intellia Therapeutics at 9.95 subject to Rule 16b-3 | 07/02/2025 |
4 | Opinion - The FDA must be modernized for the era of personalized medicine | 07/23/2025 |
5 | Intellia Therapeutics reports Q2 EPS , consensus NTLA | 08/07/2025 |
6 | Acquisition by Chase William J of 100000 shares of Intellia Therapeutics at 10.03 subject to Rule 16b-3 | 08/20/2025 |
7 | Cathie Woods Raises Wager On Ethereum-Hoarding Bitmine Ark Buys Stock Of Tom Lee-Backed Company, Dumps Shares Of Sports Betting Giant | 08/28/2025 |
8 | Cathie Woods ARK Investment buys 133K shares of Intellia Therapeutics today NTLA | 08/29/2025 |
9 | Stocks With Rising Relative Strength Intellia Therapeutics | 09/02/2025 |
10 | Why Is Xenon Pharmaceuticals Up 4.2 percent Since Last Earnings Report | 09/10/2025 |
11 | Polar Asset Management Partners Inc. Sells 250,354 Shares of Intellia Therapeutics, Inc. NTLA - MarketBeat | 09/12/2025 |
12 | Cathie Woods ARK Investment buys 615.8K shares of Intellia Therapeutics today NTLA | 09/16/2025 |
13 | Intellia Therapeutics completes enrollment in Phase 3 HAELO study of Ionov-z NTLA | 09/18/2025 |
Complementary Tools for Intellia Stock analysis
When running Intellia Therapeutics' price analysis, check to measure Intellia Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intellia Therapeutics is operating at the current time. Most of Intellia Therapeutics' value examination focuses on studying past and present price action to predict the probability of Intellia Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Intellia Therapeutics' price. Additionally, you may evaluate how the addition of Intellia Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| CEOs Directory Screen CEOs from public companies around the world |